Karim Ahmed: Why The Right DOAC Choice Still Depends on The Patient
Karim Ahmed, Clinical Pharmacist at Palm Beach Accountable Care Organization, shared a post on LinkedIn:
“One thing pharmacy continues to reinforce for me is that even when two medications are in the same class, the best choice is rarely automatic.
I was recently reviewing a comparison of Eliquis (apixaban) and Xarelto (rivaroxaban), and it served as a great reminder of how much patient-specific decision-making still matters in anticoagulation.
Both are important DOAC options for AFib and VTE, but the differences in dosing, bleeding profile, renal considerations, and overall indication breadth can meaningfully shape the right choice in practice.
A few points stood out to me.
Xarelto offers the convenience of once-daily dosing and also has additional CAD/PAD indications.
Eliquis, on the other hand, is taken twice daily and appears to have a more favorable bleeding profile in some populations, including the newer evidence referenced in the article for VTE patients.
The renal piece is also important.
The article notes that Eliquis is generally preferred over Xarelto in stage 4-5 renal impairment because of its lower renal clearance, which is one of those practical distinctions that can make a real difference when evaluating therapy options.
My biggest takeaway is this: the better anticoagulant is often the one that best fits the patient’s full clinical picture – not just the diagnosis.
Adherence, renal function, bleeding risk, comorbidities, and drug interactions all matter.
That is where clinical judgment continues to make the biggest impact.
These kinds of comparisons are always a good reminder that individualized medication management remains at the center of good patient care.”
Stay updated with Hemostasis Today.
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD
-
May 24, 2026, 17:12Silvina Graña: Helping Families Better Understand Hemophilia and Daily Life With Bleeding Disorders
-
May 24, 2026, 17:11Miikka Vikkula: Key Insights from the ISSVA 2026 World Congress
-
May 24, 2026, 17:10Mathieu Jackson: Proud to Be Present at This Historic Moment for the Global Bleeding Disorders Community
-
May 24, 2026, 17:09Ramina Fazeli: Highlighting the Emerging Role of Neutrophil Extracellular Traps in Ovarian Cancer
-
May 24, 2026, 16:12William Wallace: Normal B12 Levels May Still Cause Brain Damage and Cognitive Decline
-
May 24, 2026, 15:54Marc Carrier: Ottawa Race Weekend Raised Over 7,000 USD for Thrombosis Canada
-
May 24, 2026, 15:44Janak Sadhu: Building a Stroke-Free Mehsana Through Community Awareness and Healthcare Collaboration